Canine Osteosarcoma: ECI® and Checkpoint Inhibitor Combination Study (ECI-ICI-OSA-01)

Now enrolling. Contact the participating hospital listed below to see if your patient or dog is eligible.

Study Overview

This combination study will assess safety and efficacy of ECI® in combination with gilvetmab, a checkpoint inhibitor, as a treatment for appendicular osteosarcoma in dogs. Dogs will undergo amputation, then receive gilvetmab and ECI® over a 4-5 month period. The study will assess treatment efficacy in a metastatic disease setting and evaluate 1-year and overall survival. The gilvetmab checkpoint inhibitor has been made available for use in this study through a grant provided by Merck Animal Health.

Study Summary

• Treatment includes therapeutic amputation, gilvetmab, and ECI® immunotherapy.
• Patients must complete a 4-5 month treatment regimen and return for quarterly follow-up visits throughout the 24-month study.
• No financial assistance is available for this study, except for the gilvetmab drug product.
• Great Dane owners may qualify for financial assistance through the Great Dane Club of America.

Key Inclusion Criteria

• Eligible canine patients must be diagnosed with appendicular osteosarcoma (metastases are allowed) and must not have received prior treatment for the cancer.
• Patients must have the primary tumor in situ at the time of diagnosis.
• Enrollment is required prior to surgery (affected limb must be intact).

*Additional inclusion/exclusion criteria may apply.

Participating Locations:

• University of Missouri, College of Veterinary Medicine (Columbia, Missouri)
• MedVet Dayton Emergency Veterinary & Specialty Care (Dayton, Ohio)
• VCA Dallas Animal Specialty Hospital (Dallas, TX)

To learn more about this study and to see if your dog or canine patient may be a good candidate, contact us for more information.